#31
|
||||
|
||||
íè îäíîìó ÷åëîâåêó íå íóæíà õèìèîòåðàïèÿ, åñëè íåò ÷åòêèõ êðèòåðèåâ ëåéêåìèè, íàïðèìåð äëÿ ÎÌË:
person to be diagnosed with AML, generally 20% or more of the cells in the bone marrow or blood must be myeloblasts. êîëè÷åñòâî áëàñòîâ â ÊÌ ìîçãå ìîæåò âàðüèðîâàòü â çàâèñèì. îò ñèòóàöèè, âîò ïîñìîòðèòå êðèòåðèè äëÿ ãèïîöåëëþëÿðíîé ëåéêåìèè, ïðè êîòîðîé êîëè÷åñòâî îïóõîëåâûõ áëàñòîâ îò 5 äî 20% îò âñåõ êëåòîê ÊÌ ïëþñ â êðîâè áèöèòîïåíèÿ èëè ïàíöèòîïåíèÿ, íå òîëüêî íåéòðîïåíèÿ: âåçäå áëàñòîâ áîëåå 10% The BM blast % changed in each case according to four different estimations. Blast % in all nucleated BM cells including Iymphoid cells ranged from 20.8 to 71.0% (mean 33.7%) being less than 30% in 13 cases (40.6%). In all nucleated cells excluding lymphoid cells, blast % ranged from 38.2 to 93.7% (mean 57.3%).
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#32
|
||||
|
||||
Î÷åíü ðåäêî, íî íåðåäêî äëÿ èçîëèðîâàííîé íåéòðîïåíèè ó âçðîñëûõ, áûâàåò Large Granular Lymphocyte Syndrome, íî äëÿ åãî äèàãíîñòèêè íóæíî äåëàòü èììóíîôåíîòèïèðîâàíèå ëèìôîöèòîâ - çäåñü òåçèñû íàáëþäåíèÿ, íî èõ ëå÷èëè îò èíôåêöèé è íåéòðîïåíèè, íå ïðîñòî ëå÷èëè öèôðû íåéòðîôèëîâ
The diagnosis of LGL was based on increased LGL cells in the blood or bone marrow, most frequently increased CD 3+, CD 8+, CD 57+ cells. Increases in lymphocytes in the marrow, often in clusters were a common finding; lymphocytes in the marrow ranged from 6-79%. The range of CD 57+ in blood 11-19%, bone marrow 19-61%; CD 56+/NK cells in blood 0.06-14%, bone marrow <1-76.8%; increased CD 8+/CD 3+ in blood 1.5-90%, bone marrow <1-91%. Because most patients had neutropenia, fevers and infections we evaluated the effectiveness and safety of G-CSF therapy. Treatments were G-CSF alone (13), G-CSF with prednisone (5), G-CSF with methotrexate and prednisone (4), G-CSF with methotrexate alone (2), G-CSF with cyclosporine (1), G-CSF with cyclosporine and prednisone (1), and G-CSF with prednisone, methotrexate and cyclosporine (1). Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#33
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, çäðàâñòâóéòå! Ñïàñèáî Âàì îãðîìíîå çà îòâåòû ñ âûäåðæêàìè èç ðåêîìåíäàöèé. Óæå âòîðîé ãåìàòîëîã íà îñíîâàíèè âûëîæåííûõ â ìîåé òåìå èññëåäîâàíèé ñòàâèò ìóëüòèëèíåéíûé ÌÄÑ ñ èçáûòêîì áëàñòîâ: äèñïëàçèÿ ãðàíóëîöèòàðíîãî è ìåãàêàðèîöèòàðíîãî îòðîñòêà ( íà îñíîâàíèè òðåïàíîáèîïñèè). Õîòÿ â ðîññèéñêîé ðåêîìåíäàöèè ãåìîòîëîãè÷åñêîãî îáùåñòâà óêàçàíî, ÷òî ñëåäóåò ó÷èòûâàòü ïîêàçàòåëè êðîâè, à íå òîëüêî êîñòíûé ìîçã ( êàê Âû è ïèñàëè âûøå).
Ãîâîðÿò, íàñòðàèâàòüñÿ íà òðàíñïëàíòàöèþ â áëèæàéøèé ãîä. Ïûòàþñü ñàìà ðàçîáðàòüñÿ è åù¸ êîíñóëüòèðîâàòüñÿ, íàñêîëüêî ñðî÷íî ìíå ýòî íóæíî.Åù¸ ðàç ñïàñèáî çà ïîìîùü. |
#34
|
||||
|
||||
ïîïðîáóéòå íàéòè â Ìîñêâå Àííó Áîðèñîâíó Õëàâíî è ïîëó÷èòü åå ìíåíèå
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#35
|
|||
|
|||
Âàäèì Âïëåðüåâè÷, ñïàñèáî. Áóäó
èñêàòü. |
#36
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, çäðàâñòâóéòå! Áëàãîäàðþ çà âñå Âàøè îòâåòû ðàíåå. Õëàâíî À.Á íàøëà, ïîéäó íà êîíñóëüòàöèþ. Ïîñåòèëà òàêæå ÍÈÈ Ãåìàòîëîãèè ( â Ìîñêâå ãëàâíûé öåíòð) ,. Ïîñìîòðåâ ìîè àíàëèçû (òå æå êîòîðûå ÿ âûêëàäûâàëà â ýòîé òåìå) íàñòðàèâàþò ìåíÿ íà ïîèñê äîíîðà ( ðîäñòâåííûõ íåò) è òðàíñïîàíòàöèþ â áëèæàéøåå âðåìÿ ( åñëè äîíîð íàéäåòñÿ). ÌÄÑ ïðîÿâëÿåòñÿ òîëüêî â àíàëèçàõ ÊÌ , â êðîâè òîëüêî íåéòðîïåíèÿ, ÷óâñòâóþ ôèçè÷åñêè ÿ ñåáÿ õîðîøî. Êàðèîòèï íîðìàëüíûé. Ðèñê ïðëó÷àåòñÿ Ïðîìåæóòî÷íûé-1, ò ê.áëàñèû 6.4 Ïîíèìàþ, ÷òî ðåøàòü ÿ äîëæíà ñàìà.Õîòåëîñü áû óçíàòü ìíåíèå âðà÷à, ïðàêòèêàþùåãî â äðóãîé ñòðàíå. Íàñêîëüêî ìíå íåîáõîäèìà òðàíñïëàíòàöèÿ â áëèæàéøåå âðåìÿ. Ïðîöåäóðà î÷åíü íåïðåäñêàçóåìàÿ.
|
#37
|
||||
|
||||
âàì íóæíî âçÿòüñÿ çà ñàìî-îáðàçîâàíèå - íàíÿòü ìåä. ïåðåâîä÷èêà è ïðî÷èòàòü âñå ñàìîñò.
ó âàñ íèçêèé ðèñê (íåò ó âàñ ÌÄÑ âîîáùå, íî ïîìå÷òàåì ÷òî åñòü) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ñìîòðèòå êàðòèíêó, êîãäà ÒÊÌ ïðè âûñîêîì ðèñêå: ó âàñ ÍÅÒ íè÷åãî - âàñ äàæå íå ëå÷èëè (*high risk somatic mutations including TP53, ASXL1, and RUNX1; Blasts > 10%; transfusion dependence or severe neutropenia despite medical therapy; hypomethylating agent failure). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
|
#38
|
||||
|
||||
ïîòðàòüòå äåíüãè è ïîëó÷èòå âòîðîå ìíåíèå - òåëå-êîíñóëüòàöèÿ èç èçðàèëÿ èëè òóðöèè îò ðóññêîãîâ. âðà÷åé, à òî áóäåò ñèòóàöèÿ êàê ñ äåòñêèìè ëèìôîìàìè - äåëàþò áèîïñèþ ïðè ìîíîíóêëåîçå, íàõîäÿò áëàñòû, ñòàâÿò ëèìôîìó è çàëå÷èâàþò äåòåé äî ñìåðòè - îòñþäà â ÐÔ ëèìôîìû ó äåòåé â 10 ðàç âûøå ÷åì â äð. ñòðàíàõ...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#39
|
||||
|
||||
âîò êèòàéñêèå 40 òîâàðèùåé ó êîòîðûõ ÌÄÑ áûë ñ èçîëèð. íåéòðîïåíèåé: òîëüêî ó 7 ïðîâîäèëàñü ÒÊÌ
Watching and waiting in one subject. 12 subjects received immunosuppressive drugs including cyclosporine and lenalidomide. 9 subjects received supportive cares including RBC and/or platelet transfusions, erythropoietin (EPO) with or without granulocyte-colony stimulating factor (G-CSF). 5 received traditional Chinese medicines. 6 subjects received decitabine alone (N = 5) or with aclacinomycin, cytarabine and G-CSF (N = 1) and 7 subjects received stem cell transplant. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#40
|
||||
|
||||
ïîñìîòðèòå â òàáëèöå êàêèå äîëæíû áûòü êëåòêè â êîñòíîì ìîçãå áîëåå 10%, ÷òîáû ãîâîðèòü î ìèåëîäèñïëàçèè ãðàíóëîöèòîâ Dysgranulopoiesis [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#41
|
||||
|
||||
In refractory neutropenia (RN), dysgranulopoiesis can be identified in the blood by the presence of nuclear hypolobation and hypogranulation of neutrophils. In the bone marrow, dysplasia in the granulocytic lineage is ≥10%, with no significant dysplasia (<10%) in the erythroid or megakaryocytic lineage.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#42
|
||||
|
||||
Åùå ëå÷åíèå ÌÄÑ - âûäåëåíà Âàøà ñòàäèÿ, åñëè îí ó âàñ åñòü, ïîä÷åðêíóêî, êîãäà ÒÊÌ:
Approach to therapeutics in myelodysplastic syndromes. Patients should be risk stratified with a tool such as the IPSS-R. Some patients with lower-risk disease who have mild cytopenias and are minimally symptomatic may just be observed with serial CBCs. Patients who have anemia alone can be administered an erythropoiesis-stimulating agent if their serum erythropoietin level is less than 500 U/L, or can receive lenalidomide if they have del(5q). The approach for other patients is challenging and may involve immunosuppressive therapy with CsA and ATG, a combination growth factor approach, lenalidomide despite the absence of del(5q), or a hypomethylating agent. For patients with higher-risk disease, the key decision is whether the patient is an allogeneic stem cell transplant candidate. If the patient is a transplant candidate, the transplant should be performed as soon as possible, potentially with a hypomethylating agent as a bridge. If not, the patient should receive therapy with a hypomethylating agent; in this setting, azacitidine has improved survival compared with conventional care. “Induction” might include CPX-351 instead of the conventional cytarabine-anthracycline “3&7” combination. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#43
|
||||
|
||||
ñïðîñèòå â êëèíèêå, êàêàÿ âûæèâàåìîñòü ïîñëå ÒÊÌ ó íåðîäñòâåííîãî äîíîðà, äàæå çà ðóáåæîì åòè öèôðû íå ñëèøêîì îáíàäåæèâàþøèå, ïlþñ èììóíîñóïðåññèÿ ïëþñ ðèñê îñëîæíåíèé; òî åñòü çäîðîâóþ æåíùèíó ñ îòêëîíåíèåì â àíàëèçå ïðåâðàòÿò â ëåêàðñòâî-çàâèñèìîãî èììóíîäåïðåññèâíîãî ïàöèåíòà? ëå÷åíèå íå äîëæíî áûòü õóæå áîëåçíè, ïîåòîìó íà íà÷. ñòàäèÿõ - íàáëþäåíèå êàê íàïèñàíî âûøå; íàïîìíèëî ñëó÷àé, êîãäà çäîðîâîãî ñ àðòåôàêòíîé òðîìáîöèòîïåíèåé âðà÷è ïðåâðàòèëè ñòåðîèäàìè â áîëüíîãî ñàõàðíûì äèàáåòîì è èíôèöèðîâàííîãî òóáåðêóë¸çîì òîëüêî èç-çà ñîáñòâ. ñòðàõîâ êðîâîòå÷åíèé è ïûòàÿñü íîðìàëèçîâàòü òðîìáîöèòû...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#44
|
||||
|
||||
òåîðåòè÷åñêè âàì è ýòî íóæíî èñêëþ÷èòü - àããëþòèíàöèÿ íåéòðîôèëîâ â ïðîáèðêå â òå÷åíèå ïîëó÷àñà ïîñëå êðîâåçàáîðà ïðè ñíèæåíèè T äî êîìíàòíîé:
EDTA-induced pseudo-neutropenia resolved with kanamycin [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#45
|
|||
|
|||
Âàäèì Âàëåðüåè÷, äîáðûé âå÷åð!
Îãîðîìíàÿ áëàãîäàðíîñòü, ÷òî ïðîäîëæàåòå îòâå÷àòü íà ýòîì ôîðóìå. Ñïàñèáî çà íàâèãàöèþ ïî ìåäèöèíñêèì ñàéòàì. Ñàìà áû ÿ ïðîñòî óòîíóëà â îêåàíå èìåþùåéñÿ èíôîðìàöèè. Âíèêàþ â ñòàòüè ïî Âàøèì ññûëêàì. Ïðî òðàíñïëàíòàöèþ è ðèñêè ïîíÿëà. Íàøè âðà÷è áëàñòû--6,4 % ðàññìàòðèâàþò, êàê ïîäòâåðæäåíèå äèàãíîçà ÌÄÑ ñ ÈÁ íà 100% , ãîâîðÿò, ÷òî äðóãîé ïðè÷èíû ïîâûøåíèÿ áëàñòîâ áûòü íå ìîæåò. Çàáðàëà ñâîè áèîìàòåðèàëû äëÿ ïåðåñìîòðà äðóãèì ìîðôîëîãîì, êîòîðûé ñäåëàåò îïèñàíèå êëåòîê. Ïî ðåçóëüòàòàì áóäó êîíñóëüòèðîâàòüñÿ , êàê Âû ñîâåòîâàëè. |